Device-associated infection rates in 398 intensive care units in Shanghai, China: International Nosocomial Infection Control Consortium (INICC) findings  by Tao, Lili et al.
International Journal of Infectious Diseases 15 (2011) e774–e780Device-associated infection rates in 398 intensive care units in Shanghai, China:
International Nosocomial Infection Control Consortium (INICC) ﬁndings
Lili Tao a, Bijie Hub,*, Victor D. Rosenthal c, Xiaodong Gao b, Lixian He b
aDepartment of Respiratory Medicine, Huadong Hospital, Fudan University, Shanghai, China
bDepartment of Respiratory Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China
c International Nosocomial Infection Control Consortium, Buenos Aires, Argentina
A R T I C L E I N F O
Article history:
Received 4 January 2011
Received in revised form 11 June 2011
Accepted 20 June 2011
Corresponding Editor: Mark Holodniy,
California, USA
Keywords:
International Nosocomial Infection Control
Consortium (INICC)
Central line-associated blood stream
infection
Ventilator-associated pneumonia
Catheter-associated urinary tract infection
China
Developing country
S U M M A R Y
Objectives: To determine device-associated healthcare-associated infection (DA-HAI) rates and the
microorganism proﬁle in 398 intensive care units (ICUs) of 70 hospitals in Shanghai, China.
Methods: An open-label, prospective, cohort, active DA-HAI surveillance study was conducted on
patients admitted to 398 tertiary-care ICUs in China from September 2004 to December 2009,
implementing the methodology developed by the International Nosocomial Infection Control
Consortium (INICC). The data were collected in the participating ICUs, and uploaded and analyzed at
the INICC headquarters on proprietary software. DA-HAI rates were registered by applying the
deﬁnitions of the US Centers for Disease Control and Prevention (CDC) National Healthcare Safety
Network (NHSN). We analyzed the rates of DAI-HAI, ventilator-associated pneumonia (VAP), central
line-associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI),
and their microorganism proﬁles.
Results: During the 5 years and 4 months of the study, 391 527 patients hospitalized in an ICU for an
aggregate of 3 245 244 days, acquired 20 866 DA-HAIs, an overall rate of 5.3% (95% conﬁdence interval
(CI) 5.3–5.4) and 6.4 (95% CI 6.3–6.5) infections per 1000 ICU-days. VAP posed the greatest risk (20.8 per
1000 ventilator-days, 95% CI 20.4–21.1), followed by CAUTI (6.4 per 1000 catheter-days, 95% CI 6.3–6.6)
and CLABSI (3.1 per 1000 catheter-days, 95% CI 3.0–3.2). The most common isolated microorganism was
Acinetobacter baumannii (19.1%), followed by Pseudomonas aeruginosa (17.2%), Klebsiella pneumoniae
(11.9%), and Staphylococcus aureus (11.9%).
Conclusions: DA-HAIs in the ICUs of Shanghai pose a far greater threat to patient safety than in ICUs in the
USA. This is particularly the case for the VAP rate, which is much higher than the rates found in developed
countries. Active infection control programs that carry out infection surveillance and implement
prevention guidelines can improve patient safety and must become a priority.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Surveillance of device-associated healthcare-associated infec-
tion (DA-HAI) in the intensive care unit (ICU) represents a
prominent tool in hospital infection control and quality assurance
in many industrialized countries, including the USA.1 In this
respect, the US Centers for Disease Control and Prevention (CDC)
Study of the Efﬁcacy of Nosocomial Infection Control (SENIC) has
reported that surveillance plays a leading role in the reduction of
DA-HAIs.2
Similarly, it has been increasingly reported in scientiﬁc studies
that DA-HAIs pose the primary threat to patient safety in the ICU,* Corresponding author.
E-mail address: hubijie@vip.sina.com (B. Hu).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.06.009and are among the principal causes of patient morbidity and
mortality.3–5 The CDC’s previous National Nosocomial Infection
Surveillance System (NNIS) and current National Healthcare Safety
Network (NHSN) have established standardized criteria for DA-HAI
surveillance.6,7 This standardized surveillance method allows
infection control practitioners (ICPs) to determine DA-HAI rates
per 1000 device-days, which can be used as benchmarks among
different healthcare centers. It also provides ICPs with an in-depth
look at the institutional problems they are confronted with, so that
they can design an effective strategy to solve them. The device
utilization (DU) ratio constitutes an extrinsic risk factor for DA-
HAI.8 The DU ratio also comprises a marker for severity of illness in
patients vis-a`-vis patient susceptibility to DA-HAI.In the context of
an expanded framework for DA-HAI control, it is in high-income
countries that most of the relevant studies of ICU-acquired
infections have been conducted;9 in the developing countries,ses. Published by Elsevier Ltd. All rights reserved.
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using standardized deﬁnitions is scarce.10–18
The International Nosocomial Infection Control Consortium
(INICC) was founded in 1998, after selected hospitals from Latin
America were invited to participate in the project to measure DA-
HAI using standardized deﬁnitions and methodology.19 Shortly
afterwards, other hospitals located in different parts of the world
joined the Consortium. At present, the INICC comprises a
worldwide network with hospitals in 40 countries of Latin
America, Asia, Africa, and Europe.10–18
On a monthly basis, healthcare facilities send data to the INICC,
which are then entered into an international database. Hospital
members of the INICC provide general medical and surgical
inpatient services to adults and children hospitalized in the ICUs.
In China, published data on DA-HAI rates are not available in the
English language. The ﬁndings of the present study in Shanghai
form an integral part of the INICC and reﬂect the outcome
surveillance data that were systematically collected.
2. Methods
2.1. Setting
This study was carried out in 398 ICUs of 70 hospitals, from
September 2004 to December 2009. The hospitals have an infection
control team composed of physicians and ICPs with experience in
infection control. The infection control teams include at least one full
time physician and several infection control nurses. The nurses
involved are all professionals and work full-time in infection control.
They are responsible for collecting information from patients, and
once a DAI is suspected, they report it to the physician for an
immediate diagnosis. The ICPs listed in Table 1 work full time, but at
each hospital there are also several part-time nurses who also
collaborate in the diagnosis of DAI. The ICPs in Shanghai are all
trained by the Municipal Infection Control Center. This center
provides training courses twice a year, and each course lasts
approximately 3–5 days. The performances of the ICPs in these 70
hospitals are assessed by the Municipal Infection Control Center each
year.
The clinical microbiology laboratory provides in vitro suscepti-
bility testing of clinical isolates using standardized methods. All
the hospitals analyzed the samples in their own microbiology
laboratories. This analysis included routine culture of the speci-
mens and conventional phenotypic identiﬁcation using automated
machines (BD Phoenix or VITEK 2) or API strips. The sensitivity of
the microorganisms was deﬁned by the automated machines (BD
Phoenix or VITEK 2) or by drug sensitive slips method.
The nurse-to-patient ratio is 2–2.5:1 in the participating ICUs,
as required by the Quality Control Center of Critical Medicine and
Infection Control. The institutional review boards of the hospitals
approved the study protocol. Patient conﬁdentiality was protected
by codifying the recorded information, making it only identiﬁable
to the infection control team.Table 1
Features of the participating hospitals, Shanghai, 2004–2009
Variable Hospital (N = 70) n (%)
Type of hospital Academic 33 (47%)
Public 37 (53%)
Complexity level Level 2 36 (51%)
Level 3 34 (49%)
Number of ICPs 1 ICP 34 (49%)
2–3 ICPs 28 (40%)
>3 ICPs 8 (11%)
ICP, infection control practitioner.Fifty-one percent of the participating hospitals are categorized
as ‘complexity level 2’ (which means that they are hospitals in
medium-size cities, counties, or districts, with more than 100 beds,
but fewer than 500), and 49% as ‘complexity level 3’ (general or
comprehensive hospital at the national, provincial, or city level,
with more than 500 beds) (Table 1)
2.2. Surveillance
On a daily basis, data were collected by the infection control
teams prospectively from all the patients admitted to the ICUs by
means of speciﬁcally designed forc the DA-HAI deﬁnitions
provided by the CDC-NNIS and CDC-NHSN.6,7
ICUs were stratiﬁed into types according to the patient
population: adult ICU or pediatric ICU.
The identity of all INICC Shanghai hospitals is conﬁdential, in
accordance with the INICC Charter.
Device-days consisted of the total number of central line (CL)-
days, urinary catheter (UC)-days, or mechanical ventilator (MV)-
days.
2.3. DA-HAI rate calculations
Outcomes measured during the surveillance period included
the incidence density rate of central line-associated blood stream
infection (CLABSI; number of CLABSI divided by 1000 CL-days and
multiplied by 1000); catheter-associated urinary tract infection
(CAUTI; number of CAUTI divided by 1000 UC-days and multiplied
by 1000); and ventilator-associated pneumonia (VAP; number of
VAP divided by 1000 MV-days and multiplied by 1000).
DU ratios were calculated by dividing the total number of
device-days by the total number of bed-days.20
2.4. Statistical analysis
EpiInfo version 6.04b (CDC, Atlanta, GA, USA) and SPSS 16.0
(SPSS Inc. an IBM company, Chicago, IL, USA) were used to perform
the data analysis.
Chi-square analyses for dichotomous variables and the t-test for
continuous variables were used to analyze baseline differences
among rates. Relative risk (RR) ratios, 95% conﬁdence intervals
(CIs), and p-values were determined for all outcomes. The level of
signiﬁcance was set at p < 0.05.
3. Results
During the 5 years and 4 months of the study, 391 527 patients
hospitalized in an ICU for an aggregate of 3 245 244 days acquired
20 866 DA-HAIs, an overall rate of 5.3% (95% CI 5.3–5.4) of DA-HAIs
and 6.4 (95% CI 6.3–6.5) DA-HAIs per 1000 ICU-days. The
characteristics of the 398 ICUs at INICC Shanghai hospitals that
contributed data to this report are shown in Table 1.
The overall CLABSI rate was 3.1 (95% CI 3.0–3.2). The highest
CLABSI rate was found in the medical ICUs: 4.3 per 1000 CL-days
(95% CI 3.7–5.0), and the lowest rates in the burn ICUs and trauma
ICUs (0.0 and 1.1 per 1000 CL-days, respectively). The difference
between the medical and trauma ICUs was signiﬁcant (RR 0.86,
95% CI 1.71–8.72, p = 0.0004). The DU ratio of CL was higher in
trauma ICUs at 0.41, than in the medical ICUs at 0.18 (p < 0.001)
(Tables 2 and 3).
The VAP rate was 20.8 (95% CI 20.4–21.1) in all the ICUs
combined. The highest VAP rate was found in the trauma ICUs:
39.2 per 1000 MV-days (95% CI 33.5–45.5), and the lowest in the
burn ICUs: 7.5 per 1000 MV-days (95% CI 0.1–40.9). However, the
difference in the VAP rates between these ICUs was not signiﬁcant
Table 2
Pooled means and 95% conﬁdence intervals of the distribution of central line-associated blood stream infection rates (per 1000 central line-days) by type of adult and
pediatric ICU.
Type of ICU No. of ICUs No. of patients No. of CLABSI CL-days Pooled mean CLABSI rate 95% CI
Burn ICU 8 169 0 351 0.0 -
Cardiothoracic ICU 48 61 189 332 166 943 2.0 1.8–2.2
Coronary care ICU 59 88 287 190 59 337 3.2 2.7–3.7
General ICU 47 64 707 719 198 871 3.6 3.4–3.9
Medical ICU 53 24 664 164 38 207 4.3 3.7–5.0
Neurosurgical ICU 43 26 944 145 64 521 2.2 1.9–2.6
Pediatric ICU 19 17 365 68 19 462 3.5 2.7–4.4
Respiratory ICU 48 10 668 84 30 598 2.7 2.2–3.4
Surgical ICU 64 95 491 870 251 631 3.5 3.2–3.7
Trauma ICU 9 2043 6 5394 1.1 0.4–2.4
Overall 398 391 527 2578 835 315 3.1 3.0–3.2
ICU, intensive care unit; CLABSI, central line-associated blood stream infection; CL, central line; CI, conﬁdence interval.
Table 3
Pooled means and 95% conﬁdence intervals of central line utilization ratios by type of adult and pediatric ICU
Type of ICU No. of ICUs CL-days Patient-days Pooled mean DUR 95% CI
Burn ICU 8 351 663 0.53 0.49–0.57
Cardiothoracic ICU 48 166 943 416 574 0.40 0.39–40.1
Coronary care ICU 59 59 337 691 444 0.09 0.08–0.09
General ICU 47 198 871 655 734 0.30 0.30–0.30
Medical ICU 53 38 207 213 547 0.18 0.18–0.18
Neurosurgical ICU 43 64 521 235 930 0.27 0.27–0.28
Pediatric ICU 19 19 462 195 671 0.10 0.09–0.10
Respiratory ICU 48 30 598 123 524 0.25 0.24–0.25
Surgical ICU 64 251 631 699 138 0.36 0.36–0.36
Trauma ICU 9 5394 13 019 0.41 0.41–0.43
Overall 398 835 315 3 245 244 0.26 0.26–0.26
ICU, intensive care unit; CL, central line; DUR, device use ratio; CI, conﬁdence interval.
Table 4
Pooled means and 95% conﬁdence intervals of the distribution of ventilator-associated pneumonia rates (per 1000 mechanical ventilator-days) by type of adult and pediatric
ICU
Type of ICU No. of ICUs No. of patients No. of VAP MV-days Pooled mean VAP rate 95% CI
Burn ICU 8 169 1 134 7.5 0.1–40.9
Cardiothoracic ICU 48 61 189 975 78 901 12.4 11.6–13.1
Coronary care ICU 59 88 287 437 25 507 17.1 16.0–18.8
General ICU 47 64 707 4103 165 007 24.9 24.1–25.6
Medical ICU 53 24 664 535 25 219 21.2 19.5–23.1
Neurosurgical ICU 43 26 944 1487 63 360 23.5 22.3–24.7
Pediatric ICU 19 17 365 220 20 806 10.6 9.2–12.1
Respiratory ICU 48 10 668 676 31 186 21.7 20.0–23.4
Surgical ICU 64 95 491 2626 126 230 20.8 20.2–21.6
Trauma ICU 9 2043 164 4186 39.2 33.5–45.5
Overall 398 391 527 11 224 540 536 20.8 20.4–21.1
ICU, intensive care unit; VAP, ventilator associated pneumonia; MV, mechanical ventilator; CI, conﬁdence interval.
Table 5
Pooled means and 95% conﬁdence intervals of mechanical ventilator utilization ratios by type of adult and pediatric ICU
Type of ICU No. of ICUs MV-days Patient-days Pooled mean DUR 95% CI
Burn ICU 8 134 663 0.20 0.17–0.23
Cardiothoracic ICU 48 78 901 416 574 0.19 0.18–0.19
Coronary care ICU 59 25 507 691 444 0.04 0.04–0.04
General ICU 47 165 007 655 734 0.25 0.25–0.25
Medical ICU 53 25 219 213 547 0.12 0.11–0.12
Neurosurgical ICU 43 63 360 235 930 0.27 0.27–0.27
Pediatric ICU 19 20 806 195 671 0.11 0.10–0.11
Respiratory ICU 48 31 186 123 524 0.25 0.25–0.25
Surgical ICU 64 126 230 699 138 0.18 0.18–0.18
Trauma ICU 9 4186 13 019 0.32 0.31–0.33
Overall 398 540 536 3 245 244 0.17 0.17–0.17
ICU, intensive care unit; DUR: device use ratio; MV, mechanical ventilator; CI, conﬁdence interval.
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Table 6
Pooled means and 95% conﬁdence intervals of the distribution of catheter-associated urinary tract infection rates (per 1000 urinary catheter-days) by type of adult and
pediatric ICU
Type of ICU No. of ICUs No. of patients No. of CAUTI UC-days Pooled mean CAUTI rate 95% CI
Burn ICU 8 169 0 452 0.0 -
Cardiothoracic ICU 48 61 189 206 144 694 1.4 1.2–1.6
Coronary care ICU 59 88 287 1050 82 220 12.8 12.0–13.6
General ICU 47 64 707 2596 297 760 8.7 8.4–9.1
Medical ICU 53 24 664 637 67 243 9.5 8.7–10.2
Neurosurgical ICU 43 26 944 585 129 187 4.5 4.2–4.9
Pediatric ICU 19 17 365 39 14 742 2.6 1.9–3.6
Respiratory ICU 48 10 668 331 41 392 8.0 7.2–8.9
Surgical ICU 64 95 491 1550 312 618 5.0 4.7–5.2
Trauma ICU 9 2043 70 7707 9.1 7.1–11.5
Overall 398 391 527 7064 1 098 015 6.4 6.3–6.6
ICU, intensive care unit; CAUTI, catheter-associated urinary tract infection; UC, urinary catheter; CI, conﬁdence interval.
Table 7
Pooled means and 95% conﬁdence intervals of urinary catheter utilization ratios by type of adult and pediatric ICU
Type of ICU No. of ICUs UC-days Patient-days Pooled mean DUR 95% CI
Burn ICU 8 452 663 0.68 0.65–0.72
Cardiothoracic ICU 48 144 694 416 574 0.35 0.35–0.35
Coronary care ICU 59 82 220 691 444 0.12 0.12–0.12
General ICU 47 297 760 655 734 0.45 0.45–0.46
Medical ICU 53 67 243 213 547 0.31 0.31–0.32
Neurosurgical ICU 43 129 187 235 930 0.55 0.55–0.56
Pediatric ICU 19 14 742 195 671 0.08 0.07–0.08
Respiratory ICU 48 41 392 123 524 0.34 0.33–0.34
Surgical ICU 64 312 618 699 138 0.45 0.45–0.45
Trauma ICU 9 7707 13 019 0.59 0.58–0.60
Overall 398 1 098 015 3 245 244 0.34 0.34–0.34
ICU, intensive care unit; DUR, device use ratio; UC, urinary catheter; CI, conﬁdence interval.
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0.32 (Tables 4 and 5).
The overall CAUTI rate was 6.4 (95% CI 6.3–6.6). The highest
CAUTI rate was found in the coronary care ICUs: 12.8 per 1000 UC-
days (95% CI 12.0–13.6), and the lowest rates in the burn and
cardiothoracic ICUs: 0.0 and 1.4 per 1000 UC-days, respectively.
The difference between coronary care and cardiothoracic ICUs was
signiﬁcant regarding the CAUTI rate (p < 0.001) and the UC DU
ratio (0.12 in coronary care ICUs compared to 0.35 in cardiotho-
racic ICUs, p < 0.001). The highest UC DU ratio was found in the
burn ICUs: 0.68. (Tables 6 and 7).
Table 8 shows the DA-HAI rates stratiﬁed by hospital size. The
highest CLABSI rate was found in the larger-size hospitals, whoseTable 9
Pooled means and 95% conﬁdence intervals of the distribution of device-associated inf
Hospital size No. of patients CLABSI rate (95% 
2004 18 335 3.0 (2.4–3.6) 
2005 65 080 2.5 (2.3–2.8) 
2006 69 010 2.8 (2.5–3.1) 
2007 80 841 2.7 (2.2–3.0) 
2008 78 012 4.3 (4.0–4.6) 
2009 80 249 3.0 (2.7–3.2) 
CI, conﬁdence interval; CLABSI, central line-associated blood stream infection; VAP, ve
Table 8
Pooled means and 95% conﬁdence intervals of the distribution of device-associated inf
Hospital size No. of patients CLABSI rate (95%
200–500 beds 51 854 3.4 (3.0–3.7) 
501–800 beds 144 796 2.2 (2.0–2.4) 
801 beds 194 877 3.5 (3.4–3.7) 
CI, conﬁdence interval; CLABSI, central line-associated blood stream infection; VAP, verate (3.4 per 1000 CL-days) was signiﬁcantly higher than that in the
medium-size hospitals (2.2 per 1000 CL-days) (RR 1.57, 95% CI
1.43–1.73, p < 0.001). The CAUTI rate, however, was higher in the
smaller-size hospitals (8.0 per 1000 UC-days) than in the larger
ones (5.6 per 1000 UC-days) (RR 1.44, 95% CI 1.34–1.55, p < 0.01).
VAP rates were similar for all hospital sizes.
Table 9 shows the evolution of DA-HAI rates by year. It is
noteworthy that the VAP rate improved over the years, decreasing
from 26.0 (24.0–28.2) in 2004 to 15.8 (15.1–16.5) in 2009; this
reduction of 39% was signiﬁcant (RR 0.61, 95% CI 0.55–0.66,
p < 0.01). The CAUTI rate also declined, from 7.4 to 4.9 (RR 0.67,
95% CI 0.59–0.75, p < 0.001). However, CLABSI rates remained
stable. We also noticed that the overall VAP rate was higher in theection rates (per 1000 invasive device-days) by year
CI) VAP rate (95% CI) CAUTI rate (95% CI)
26.0 (24.0–28.2) 7.4 (6.7–8.2)
23.2 (22.2–24.2) 7.2 (6.8–7.6)
23.6 (22.7–24.7) 7.4 (7.0–7.8)
22.3 (21.5–23.2) 6.4 (6.1–6.7)
19.0 (18.1–19.8) 6.4 (6.1–6.7
15.8 (15.1–16.5) 4.9 (4.6–5.2)
ntilator associated pneumonia; CAUTI, catheter-associated urinary tract infection.
ection rates (per 1000 invasive device-days) by hospital size
 CI) VAP rate (95% CI) CAUTI rate (95% CI)
20.2 (19.1–21.4) 8.0 (7.5–8.6)
20.9 (20.2–21.6) 7.5 (7.2–7.7)
20.8 (20.3–21.3) 5.6 (5.4–5.7)
ntilator associated pneumonia; CAUTI, catheter-associated urinary tract infection.
Table 10
Comparison of DA-HAI rates (per 1000 device-days) in the ICUs of the International
Nosocomial Infection Control Consortium (INICC) Shanghai hospitals and the US
National Healthcare Safety Network (US NHSN)
INICC Shanghai,
China 2004–2009
Pooled mean
(95% CI)
INICC 2004–2009
Pooled mean
(95% CI)
US NHSN
2006–2008
Pooled mean
(95% CI)
Medical ICU
CLABSI 4.3 (3.7–5.0) 14.7 (13.8–15.6) 1.9 (1.8–2.0)
CAUTI 9.5 (8.7–10.2) 6.3 (5.8–6.8) 3.9 (3.7–4.2)
VAP 21.2 (19.5–23.1) 7.7 (7.1–8.3) 2.2 (2.0–2.4)
Surgical ICU
CLABSI 3.5 (3.2–3.7) 5.0 (4.7–5.4) 2.3 (2.2–2.4)
CAUTI 5.0 (4.7–5.2) 5.0 (4.7–5.4) 4.3 (4.1–4.5)
VAP 20.8 (20.2–21.6) 16.3 (15.7–17.0) 4.9 (4.6–5.1)
Pediatric ICU
CLABSI 3.5 (2.7–4.4) 10.7 (9.9–11.5) 3.0 (2.8–3.2)
CAUTI 2.6 (1.9–3.6) 4.7 (4.1–5.5) 4.2 (3.8–4.7)
VAP 10.6 (9.2–12.1) 6.5 (5.9–7.1) 1.8 (1.6–2.1)
DA-HAI, device-associated healthcare-associated infections; ICU, intensive care
unit; CI, conﬁdence interval; CLABSI, central line-associated bloodstream infection;
CAUTI, catheter-associated urinary tract infection; VAP, ventilator-associated
pneumonia.
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17.4, p < 0.01), and was also higher in the medium-complexity
hospitals as compared with the high-complexity ones (25.0 vs.
19.0, p < 0.01).
Table 10 compares overall rates of CLABSI, CAUTI, and VAP in
the INICC Shanghai ICUs and CDC NHSN ICUs. (1) Although NHSN
rates were lower in the medical and surgical ICUs for all infection
types, in the pediatric ICUs, the CLABSI rates were similar and the
CAUTI rate was higher in the NHSN than in this study (4.2
compared to 2.6 per 1000 UC-days).
Table 11 shows the distribution of the 9043 isolated pathogens
involved in device-associated infections. Acinetobacter baumannii
was the most common microorganism (19.1%), followed by
Pseudomonas aeruginosa. This indicates that Gram-negative
bacteria were the most frequent overall. Staphylococcus aureus
was the most common organism in CLABSI patients and Candida
spp in CAUTI patients.Table 11
Distribution of pathogens involved in DA-HAI
Microorganism related
to DA-HAI
CLABSI-
related
(n = 845)
VAP-
related
(n = 6151)
CAUTI-
related
(n = 2047)
Overall
(n = 9043)
Acinetobacter baumannii 12.3% 25.4% 3.0% 19.1%
Pseudomonas aeruginosa 5.1% 23.5% 3.3% 17.2%
Klebsiella pneumoniae 6.9% 14.6% 5.8% 11.9%
Staphylococcus aureus 15.9% 15.0% 1.2% 11.9%
Candida spp 14.0% 1.4% 35.7% 10.4%
Escherichia coli 10.1% 5.1% 19.1% 8.7%
Enterococcus faecium 1.7% 0.0% 13.3% 3.2%
Stenotrophomonas spp 1.9% 4.2% 0.1% 3.1%
Enterobacter spp 3.3% 2.6% 2.4% 2.6%
Enterococcus faecalis 5.1% 0.0% 8.5% 2.4%
Other Staphylococcus 14.1% 0.2% 2.6% 2.0%
Other Gram-negative 2.2% 1.9% 1.3% 1.8%
Other Pseudomonas 1.3% 1.7% 0.7% 1.4%
Proteus spp 0.6% 1.2% 1.1% 1.1%
Flavobacterium spp 0.5% 0.9% 0.1% 0.7%
Streptococcus spp 1.7% 0.0% 0.7% 0.3%
Other pathogens 3.3% 2.1% 1.1% 2.2%
DA-HAI, device-associated healthcare-associated infections; CLABSI, central line-
associated blood stream infection; VAP, ventilator-associated pneumonia; CAUTI,
catheter-associated urinary tract infection.4. Discussion
It has been 30 years since the effectiveness of implementing an
integrated infection control program focused on HAI surveillance
was demonstrated. As reported in the many studies conducted in
the USA, the incidence of HAI may be reduced by as much as 30%,
enabling a feasible associated reduction in healthcare costs.21 For
more than 30 years, the CDC’s NNIS/NHSN network has provided
benchmark US ICU data on DAIs and antibiotic resistance, which
have proven invaluable for researchers, and have served as an
inspiration to the INICC program.1,8,22–27 Initially, INICC surveil-
lance was concentrated on DAI surveillance in the ICU, a healthcare
setting with the highest HAI rates, in which patient safety is most
seriously threatened, due to their critical condition and exposure
to invasive devices.28 In our study the most frequently isolated
microorganism was A. baumannii, followed by P. aeruginosa. We
had positive sputum culture results from 74% of all study patients
with VAP, 25% of which were positive for Acinetobacter sp. In a
previous study conducted in Hubei, China, P. aeruginosa was the
most common microorganism, followed by Escherichia coli and A.
baumannii.29 In a different study also carried out in China in 2002,
A. baumannii was the most common microorganism.30
The rate of device use in Shanghai ICUs is lower than that
reported in US ICUs by the NNIS/NHSN system.1,25,27 However, DA-
HAI rates identiﬁed in Shanghai ICUs were higher than the
published US rates (Table 9).1,27 Although the difference in CLABSI
and CAUTI is not considered signiﬁcant, the VAP rate in Shanghai is
particularly high in the ICUs in this study in comparison to the
NNIS/NHSN rates. In a recent KISS (Krankenhaus Infektions
Surveillance System) study in Germany, the VAP rate was 5.44,
which is higher than that reported in the NHSN, but again still
much lower than the rate found in our study.31
In the surgical ICUs of the Shanghai INICC network, the CLABSI
rate was lower than the INICC pooled rates, the CAUTI rate was
similar, and the VAP rate was higher. In the medical ICUs of the
Shanghai INICC network, the CLABSI rate was lower than the INICC
pooled rate, but the CAUTI rate and the VAP rate were higher. In the
pediatric ICUs of the Shanghai INICC network, the CLABSI and
CAUTI rates were lower than the INICC pooled rates and the VAP
rate was higher.13
These higher DA-HAI rates may reﬂect the typical ICU situation
in limited-resource countries as a whole.32–34 Among the primary
plausible causes, it should be mentioned that, in the majority of
limited-resource countries, adherence to infection control pro-
grams is irregular.
Although few patients receive non-invasive ventilation in the
ICU, device utilization rates are low in China. The severity of illness
in patients is not frequently evaluated, so patients are not
discharged from the ICU in a timely manner, which could partly
explain the low utilization rate. To reduce the risk of infection in
hospitalized patients, DA-HAI surveillance is of primary impor-
tance, because it effectively describes and addresses the impor-
tance and characteristics of the threatening situation created by
DA-HAIs. This must be followed by the implementation of
practices aimed at DA-HAI prevention and control. Additionally,
participation in the INICC has played a fundamental role, not only
in increasing the awareness of DAI risks in the INICC ICUs, but also
in providing an exemplary basis for the institution of infection
control practices. In many INICC ICUs, for example, the high
incidence of DA-HAI has been reduced by carrying out targeted
performance feedback programs for hand hygiene, and central-
line, ventilator, and urinary catheter care.15,35–41 Finally, to
effectively control antibiotic resistance, the administration of
anti-infectives must be restricted.
To compare a hospital’s DA-HAI rates and DU ratios with the
rates identiﬁed in this report, it is required that the hospital
L. Tao et al. / International Journal of Infectious Diseases 15 (2011) e774–e780 e779concerned start collecting their data by applying the methods and
methodology described by the CDC NHSN and INICC, and then
calculate infection rates and DU ratios for the device-associated
module.
The particular and primary application of these data is to serve
as a guide for the implementation of prevention strategies and
other quality improvement efforts locally, in order to help reduce
DA-HAI rates to the minimum possible level.
To conclude, the data reported in this study strengthen the fact
that DA-HAIs, particularly in ICU patients from low-income
countries, must be regarded as a serious and often concealed
threat to patient safety, as compared to the developed world. It is
the primary objective of the INICC to foster infection control
practices by facilitating elemental, feasible, and inexpensive tools
and resources to tackle this problem effectively and systematically,
leading to greater and stricter adherence to infection control
programs and guidelines, and to the correlated reduction in DA-
HAI and their adverse consequences in the ICUs participating in the
INICC, as well as at any other healthcare facility in the developing
world.
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